SCHEMBL3483870

SCHEMBL3483870

O=C(/C=C/c1ccc(O)cc1)c1ccc(NS(=O)(=O)c2ccc(F)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.60
KDM4E B2RXH2 2/20 0.60
TNFRSF1A P19438 1/20 0.58
F3 P13726 1/20 0.56
MEN1 O00255 2/20 0.55
LMNA P02545 2/20 0.55
KMT2A Q03164 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
ALDH1A1 P00352 1/20 0.55
GAA P10253 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MMP1 P03956 1/20 0.53
MMP2 P08253 1/20 0.53
MMP9 P14780 1/20 0.53
HDAC1 Q13547 2/20 0.53
HDAC3 O15379 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
HDAC8 Q9BY41 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483873 1.00 MAPT (0.60) MAPTKDM4ETNFRSF1AF3MEN1
SCHEMBL3483881 0.94 F3 (0.64) MAPTKDM4EF3MEN1LMNA
SCHEMBL3483883 0.94 F3 (0.64) MAPTKDM4EF3MEN1LMNA
SCHEMBL3484498 0.88 F3 (0.56) MAPTKDM4EF3MEN1LMNA
SCHEMBL3484501 0.88 F3 (0.56) MAPTKDM4EF3MEN1LMNA
SCHEMBL25200492 0.88 ESR1 (0.68) MAPTKDM4EF3MEN1LMNA
SCHEMBL3483827 0.88 LMNA (0.71) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL25212501 0.88 MAOB (0.68) MAPTKDM4EF3MEN1LMNA
SCHEMBL3483831 0.88 LMNA (0.71) MAPTKDM4EMEN1LMNAKMT2A
SCHEMBL3483693 0.88 HDAC3 (0.66) MAPTKDM4EF3MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP claimed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US claimed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP claimed
US-7851654-B2 Chalcone derivatives, pharmaceutically acceptable salt, method for preparation and uses thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2010-12-14 US claimed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US claimed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US claimed
EP-2099440-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS Seoul National University Industry Foundation (KR) 2009-09-16 EP claimed
WO-2008069608-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) 2008-06-12 WO claimed
WO-2007114532-A1 NOVEL CHALCONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR PREPARATION AND USES THEREOF INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2007-10-11 WO claimed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP disclosed
US-9072698-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2015-07-07 US disclosed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US disclosed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US disclosed
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSTIY (KR) 2009-10-08 US disclosed
EP-2099440-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS Seoul National University Industry Foundation (KR) 2009-09-16 EP disclosed
WO-2008069608-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONALUNIVERSITY INDUSTRY FOUNDATION (KR) 2008-06-12 WO disclosed
WO-2007114532-A1 NOVEL CHALCONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR PREPARATION AND USES THEREOF INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090252694-A1 Novel Chalcone Derivatives, Pharmaceutically Acceptable Salt, Method for Preparation and Uses Thereof TYR, CYP21A2, CMA1 MAPT 4199/4885KDM4E 1529/4885TNFRSF1A 4825/4885
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS TM9SF4, TM9SF2, TM9SF3 MAPT 4397/4885KDM4E 357/4885TNFRSF1A 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.